Loading organizations...
§ Private Profile · 400 N Aberdeen St, Chicago, IL, USA
Biotechnology company developing next-generation cell therapies for solid tumors with a non-invasive approach.
CTRL Therapeutics is a Chicago biotechnology company developing advanced cell therapies for solid tumors by extracting circulating tumor-reactive lymphocytes directly from a patient's blood. This noninvasive approach eliminates the need for surgically removed tumor tissue, aiming to broaden treatment access for solid tumors, which represent 90% of adult cancers. Operating with fewer than 25 employees, the enterprise has secured $10 million across two seed funding rounds to advance its proprietary platform. This financial backing is led by venture capital firm General Catalyst, with additional participation from institutional investors including Intermountain Health and FACIT. Recently appointing Derrell Porter MD as Chief Executive Officer, the firm has also published its initial mouse model antitumor efficacy results in Nature Biomedical Engineering. The immunotherapy startup was officially founded in 2022 by lead researcher Shana Kelley alongside a team of experts.
CTRL Therapeutics has raised $10.0M across 1 funding round.
CTRL Therapeutics has raised $10.0M in total across 1 funding round.
CTRL Therapeutics has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Seed in April 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2023 | $10M Seed | General Catalyst | ARCH Venture Partners, F Prime Capital, FTX Ventures, LUX Capital, Mubadala, Y Combinator, Arash Ferdowsi, Balaji Srinivasan, Eoghan Mccabe, Karim Atiyeh, Scott Belsky, Facit, Intermountain Ventures | Announced |
CTRL Therapeutics has raised $10.0M in total across 1 funding round.
CTRL Therapeutics's investors include General Catalyst, ARCH Venture Partners, F-Prime Capital Partners, FTX Ventures, Lux Capital, Mubadala, Y Combinator, Arash Ferdowsi, Balaji Srinivasan, Eoghan McCabe, Karim Atiyeh, Scott Belsky.
cTRL Therapeutics is a biotechnology company developing next-generation autologous cell therapies for solid tumors, which account for 90% of all cancers.[1][2][6] It builds polyclonal cell therapies using its proprietary IsoQore™ platform to isolate and expand circulating tumor-reactive lymphocytes (cTRLs) from peripheral blood, serving cancer patients by addressing limitations of existing therapies like tumor-infiltrating lymphocytes (TILs) that require invasive surgery.[2][3][5][6] The lead product, cTRL-001, targets a broad range of solid tumors with a safer, scalable, outpatient-ready approach, currently in preclinical development with clinical trials planned for 2025; the company raised $10M in seed funding in 2023 and continues to secure investments for expansion.[3][4][5]
Founded in 2022 and headquartered in San Francisco with growing operations in Toronto, cTRL demonstrates strong early momentum through key hires, lab expansions, and partnerships like Princess Margaret Cancer Centre.[1][4][5]
cTRL Therapeutics was founded in 2022 by an experienced team of biotech entrepreneurs, including Shana Kelley, Ph.D., who serves as Chief Technology Officer and highlighted the need for better tools to isolate tumor-reactive cells for solid tumors.[1][3] The idea emerged from challenges in cell therapy: TIL therapies rely on exhausted cells from surgically removed tumors, while TCR therapies lack sufficient tumor-specific targets; cTRL's approach leverages potent cTRLs already circulating in blood for a non-invasive alternative.[3][6]
Early traction included a $10M seed round in April 2023 led by General Catalyst, with participation from Intermountain Health, FACIT, and others, enabling platform optimization.[3] Pivotal moments include appointing Derrell D. Porter, M.D., as CEO in November 2023 and a follow-on FACIT investment in October 2024 to establish a Toronto lab, boosting Canadian R&D capabilities.[4][5]
cTRL stands out in solid tumor cell therapy through these key advantages:
cTRL rides the cell therapy revolution shifting from blood cancers (e.g., CAR-T successes) to intractable solid tumors, where TILs and TCR therapies face scalability hurdles.[3][6] Timing aligns with advances in immune cell isolation tech and growing investor interest in biotech platforms addressing 90% of cancers; market forces like rising cancer incidence and demand for personalized, non-invasive treatments favor blood-based approaches over surgical ones.[2][6]
By simplifying manufacturing and access, cTRL influences the ecosystem toward curative therapies for more patients, potentially accelerating adoption through partnerships in hubs like Toronto's academic-clinical network.[5]
cTRL Therapeutics is poised to enter clinical trials with cTRL-001 in 2025, leveraging Toronto expansion and preclinical progress to validate its platform.[5] Trends like AI-driven cell discovery and outpatient immuno-oncologies will shape its path, potentially expanding to combination therapies amid a $100B+ solid tumor market. Its influence may grow by proving cTRLs as a TIL superior, unlocking curative options for underserved patients and drawing further venture capital.[2][3][6] This positions cTRL to redefine biotech's fight against solid tumors, building directly on its seed-fueled momentum.